Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? (Q37986567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Abby Li

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Karen Levy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Shale B Farber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Nathan Herrmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

167-179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350526%20AND%20SRC:MED&resulttype=core&format=json

Global prevalence of dementia: a Delphi consensus study

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Caregiver well-being: a multidimensional examination of family caregivers of demented adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Psychotropic drug use among caregivers of patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Caregiving as a risk factor for mortality: the Caregiver Health Effects Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Depressive symptoms in newly admitted nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Prevalence of depression and depression recognition in nursing homes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Differences in health-related quality of life between older nursing home residents without cognitive impairment and the general population of Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Burden: a review of measures used among caregivers of individuals with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Validation study of the Chinese version of the neuropsychiatric inventory (CNPI).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Caregiving and the stress process: an overview of concepts and their measures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The international development of the RGHQoL: a quality of life measure for recurrent genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The screen for caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Donepezil for the treatment of agitation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Antipsychotic use in the elderly: shifting trends and increasing costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

The caregiver reaction assessment (CRA) for caregivers to persons with chronic physical and mental impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

A systematic review of stress in staff caring for people with dementia living in 24-hour care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Elderly psychiatric patient status and caregiver perceptions as predictors of caregiver burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Validity and reliability of assessments of time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599140-000000000-00000

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

21 January 2018

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

Is caregiving hazardous to one's physical health? A meta-analysis

1 reference

12 December 2020

Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication

1 reference

12 December 2020

[Neuropsychiatric symptoms of dementia: psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI)]

1 reference

12 December 2020

The influence of a diagnosed mental impairment on family caregiver strain

1 reference

12 December 2020